Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571145 | 0.93 | CTSK (0.35) | CTSKMEN1MAPK1KMT2AAPLNR | |
| SCHEMBL2500185 | 0.93 | CTSK (0.35) | CTSKMEN1MAPK1KMT2AAPLNR | |
| SCHEMBL20338584 | 0.92 | P2RX7 (0.35) | CTSKMEN1MAPK1KMT2AAPLNR | |
| SCHEMBL20338609 | 0.92 | P2RX7 (0.35) | CTSKMEN1MAPK1KMT2AAPLNR | |
| SCHEMBL2496562 | 0.92 | P2RX7 (0.35) | CTSKMEN1MAPK1KMT2AAPLNR | |
| SCHEMBL28607231 | 0.88 | CTSK (0.35) | CTSKMEN1MAPK1KMT2AAPLNR | |
| SCHEMBL29280568 | 0.85 | GAA (0.37) | CTSKMEN1MAPK1KMT2AAPLNR | |
| SCHEMBL25645220 | 0.83 | APLNR (0.36) | CTSKMEN1MAPK1KMT2AAPLNR | |
| SCHEMBL11605307 | 0.79 | CTSK (0.36) | CTSKMEN1MAPK1KMT2AAPLNR | |
| SCHEMBL14908805 | 0.76 | MEN1 (0.37) | CTSKMEN1MAPK1KMT2AAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084842-B2 | Glucopyranosyl derivative and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-20210061839-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-03-04 | — | — | US | disclosed |
| US-20180215780-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | DFH THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180186860-A1 | SYNTHETIC APOLIPOPROTEINS, AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR NANOLIPOPROTEIN PARTICLES FORMATION | U.S. DEPARTMENT OF ENERGY | 2018-07-05 | — | — | US | disclosed |
| CN-107567438-A | Riluzole prodrug and application thereof | 拜尔哈文制药股份有限公司 | 2018-01-09 | — | — | CN | disclosed |
| US-20170008921-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-01-12 | — | — | US | disclosed |
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| EP-1685119-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2016-03-09 | — | — | EP | disclosed |
| EP-2483277-B1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2015-12-02 | — | — | EP | disclosed |
| EP-2049474-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-11-04 | — | — | EP | disclosed |
| WO-2008008776-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | disclosed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | disclosed |
| EP-1685119-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| WO-2005049593-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049594-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128706-A1 | Apoptosis promoters | BAX, BCL2, API5 | CTSK 1995/4885MEN1 4483/4885MAPK1 3503/4885 |
| US-20210061839-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SLC5A1, SLC5A2, UGGT1 | CTSK 3863/4885MEN1 3921/4885MAPK1 704/4885 |
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | CTSK 2451/4885MEN1 2933/4885MAPK1 1336/4885 |
| US-20070015787-A1 | Apoptosis promoters | BAX, BCL2, API5 | CTSK 1995/4885MEN1 4483/4885MAPK1 3503/4885 |
| US-20060258657-A1 | Apoptosis promoters | BAX, BCL2, API5 | CTSK 1995/4885MEN1 4483/4885MAPK1 3503/4885 |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | BAX, API5, CCAR2 | CTSK 2393/4885MEN1 4421/4885MAPK1 4335/4885 |
| US-20170008921-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | ERG28, CCR3, ACBD3 | CTSK 1531/4885MEN1 4454/4885MAPK1 2528/4885 |
| US-20180215780-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | ERG28, CCR3, ACBD3 | CTSK 1385/4885MEN1 4314/4885MAPK1 1939/4885 |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | BCL2A1, BAX, BCL2L1 | CTSK 2401/4885MEN1 4366/4885MAPK1 2702/4885 |
| US-11084842-B2 | Glucopyranosyl derivative and use thereof | SLC5A1, SLC5A2, UGGT1 | CTSK 3863/4885MEN1 3921/4885MAPK1 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.